Predictive value of NLR and PLR for outcome after immunotherapy in advanced urothelial carcinoma

Chen Yingye; Chen Yong; Jiang Qing; Wei Xiaohang; Sun Wei

doi:10.13406/j.cnki.cyxb.003317

您当前的位置：

首页 >

文章列表页 >

Predictive value of NLR and PLR for outcome after immunotherapy in advanced urothelial carcinoma

Other tumors of urinary system | 更新时间：2025-10-21

- Predictive value of NLR and PLR for outcome after immunotherapy in advanced urothelial carcinoma
- Journal of Chongqing Medical University Vol. 48, Issue 8, Pages: 965-970(2023)
- 作者机构：
  
  1.重庆医科大学附属第二医院泌尿外科，重庆 400010
  2.重庆大学附属涪陵医院泌尿外科，重庆 408000
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.003317
  CLC： R737.14
- Received：22 April 2023，
  
  Revised：2023-07-18，
  
  Accepted：28 August 2023，
  
  Published：28 August 2023
- 稿件说明：
移动端阅览
陈荧野,陈勇,姜庆,等.NLR及PLR对晚期尿路上皮癌免疫治疗疗效和预后的预测价值[J].重庆医科大学学报,2023,48(8):965-970.

Chen Yingye,Chen Yong,Jiang Qing,et al.Predictive value of NLR and PLR for outcome after immunotherapy in advanced urothelial carcinoma[J].Journal of Chongqing Medical University,2023,48(8):965-970.
陈荧野,陈勇,姜庆,等.NLR及PLR对晚期尿路上皮癌免疫治疗疗效和预后的预测价值[J].重庆医科大学学报,2023,48(8):965-970. DOI： 10.13406/j.cnki.cyxb.003317.

Chen Yingye,Chen Yong,Jiang Qing,et al.Predictive value of NLR and PLR for outcome after immunotherapy in advanced urothelial carcinoma[J].Journal of Chongqing Medical University,2023,48(8):965-970. DOI： 10.13406/j.cnki.cyxb.003317.

摘要

目的

探讨外周血中性粒细胞与淋巴细胞比值（neutrophil to lymphocyte ratio，NLR）和血小板与淋巴细胞比值（platelet to lymphocyte ratio，PLR）对晚期尿路上皮癌免疫治疗疗效和预后的预测价值。

方法

回顾性分析2019年9月至2022年7月接受过免疫检查点抑制剂治疗的晚期尿路上皮癌患者的临床资料，绘制受试者工作特征曲线，根据曲线下面积（area under the curve，AUC）筛选的最佳截断值分组，应用Kaplan-Meier生存分析比较组间生存差异，运用Cox模型进行多因素分析筛选出独立预测因素。

结果

共纳入57例患者，经3周期免疫治疗后NLR较治疗前显著下降（

0.001），分别为2.40±1.08和3.05±1.07；而治疗前后PLR无明显变化（

=0.402），分别为226.41±111.70和246.97±113.17；外周血中治疗前后NLR、PLR及NLR变化幅度的AUC分别为0.829 1（

=0.004）、0.889 6（

0.001）、0.743 6（

=0.003）、0.740 4（

0.001）、0.798 4（

0.001）。生存分析显示：治疗前NLR≥3.17（3.5个月vs. 未达到，

0.001）、治疗前PLR≥284.40（5.7个月vs. 9.5个月，

=0.011）、治疗后NLR≥2.41（4.8个月vs. 9.9个月，

0.001）及NLR变化幅度

19.8%（5.8个月vs. 9.5个月，

=0.004）与较差的PFS相关，而一线免疫联合化疗具有更好的PFS（9.3个月vs. 6.0个月，

=0.006），且联合治疗组NLR变化更为显著（

=0.034）。Cox多因素分析表明治疗前NLR、NLR变化幅度及合并化疗与否是晚期尿路上皮癌免疫治疗PFS的独立预测因素（

0.05）。

结论

治疗前高NLR及PLR水平预示着不良预后，一线免疫联合化疗能显著降低NLR，延长患者PFS，而NLR及其动态变化是晚期尿路上皮癌免疫治疗的独立预测因素。

Abstract

Objective

To explore the value of peripheral blood neutrophil-to-lymphocyte ratio（NLR） and platelet-to-lymphocyte ratio（PLR） in predicting the outcome after immunotherapy for advanced urothelial carcinoma.

Methods

We retrospectively analyzed the clinical data of patients with advanced urothelial carcinoma treated with immune checkpoint inhibitors from September 2019 to July 2022. The patients were grouped according to the cut-off value derived from the area under the curve（AUC）. The Kaplan-Meier method was used to compare the survival of the groups. A multivariable Cox model was used to determine independent predictive factors.

Results

A total of 57 patients were included. After three cycles of immunotherapy，NLR was significantly decreased（pre-treatment 2.40±1.08 vs. post-treatment 3.05±1.07，

0.001）. There was no significant change in PLR（pre-treatment 226.41±111.70

vs. post-treatment 246.97±113.17，

=0.402）. The AUC values of pre-NLR，post-NLR，pre-PLR，post-PLR，and delta-NLR（change in NLR） were 0.829 1（

=0.004），0.889 6（

0.001），0.743 6（

=0.003），0.740 4（

0.001），and 0.798 4（

0.001），respectively. The survival analysis showed that pre-NLR ≥3.17（3.5 months vs. not achieved，

0.001），pre-PLR≥284.40（5.7 months vs. 9.5 months，

=0.011），post-NLR ≥2.41（4.8 months vs. 9.9 months，

0.001），and delta-NLR

19.8%（5.8 months vs. 9.5 months，

=0.004） were significantly associated with a poorer PFS；first-line immunotherapy combined with chemotherapy produced a better PFS（9.3 months vs. 6.0 months，

=0.006），and NLR change was significantly greater in patients with combined treatment（

=0.034）. The multivariable Cox analysis showed that pre-NLR，delta-NLR，and whether chemotherapy was combined were independent predictors of PFS after immunotherapy in advanced urothelial carcinoma（

0.05）.

Conclusion

High levels of NLR and PLR before treatment indicate a poor prognosis. First-line immunotherapy combined with chemotherapy can reduce NLR and prolonging patients’ PFS. NLR and its change are independent predictors of outcome after immunotherapy in advanced urothelial carcinoma.

关键词

Keywords

references

Sung H ， Ferlay J ， Siegel RL . Global Cancer Statistics 2020：GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries [J ] . CA ： A Cancer Journal for Clinicians ， 2021 ， 71 （ 3 ）： 209 - 249 .

Nakamura K ， Smyth MJ . Targeting cancer-related inflammation in the era of immunotherapy [J ] . Immunol Cell Biol ， 2017 ， 95 （ 4 ）： 325 - 332 .

Cupp MA ， Cariolou M ， Tzoulaki I ， et al . Neutrophil to lymphocyte ratio and cancer prognosis：an umbrella review of systematic reviews and Meta-analyses of observational studies [J ] . BMC Med ， 2020 ， 18 （ 1 ）： 360 .

Kartolo A ， Holstead R ， Khalid S ， et al . Serum neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in prognosticating immunotherapy efficacy [J ] . Immunotherapy ， 2020 ， 12 （ 11 ）： 785 - 798 .

Valero C ， Lee M ， Hoen D ， et al . Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors [J ] . Nat Commun ， 2021 ， 12 （ 1 ）： 729 .

Gungabeesoon J ， Gort-Freitas N A ， Kiss M ， et al . A neutrophil response linked to tumor control in immunotherapy [J ] . Cell ， 2023 ， 186 （ 7 ）： 1448 - 1464 .

Hirschhorn D ， Budhu S ， Kraehenbuehl L ， et al . T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants [J ] . Cell ， 2023 ， 186 （ 7 ）： 1432 - 1447 .

Hinterleitner C ， Strähle J ， Malenke E ， et al . Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer [J ] . Nat Commun ， 2021 ， 12 （ 1 ）： 7005 .

Boussiotis VA . Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway [J ] . N Engl J Med ， 2016 ， 375 （ 18 ）： 1767 - 1778 .

Tural D ， Ölmez ÖF ， Sümbül AT ， et al . Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab [J ] . Int J Clin Oncol ， 2021 ， 26 （ 8 ）： 1506 - 1513 .

陈杰翔，廖大忠 . 血小板淋巴细胞比率、中性粒细胞淋巴细胞比率及血脂水平在膀胱尿路上皮癌中的表达及临床意义 [J ] . 中国老年学杂志， 2020 ， 40 （ 6 ）： 1172 - 1177 .

Chen JX ， Liao DZ . Expression and clinical significance of PLR，NLR and blood lipid levels in bladder urothelial carcinoma [J ] . Chinese Journal of Gerontology ， 2020 ， 40 （ 6 ）： 1172 - 1177 .

Rojo F ， Corassa M ， Mavroudis D ， et al . International real-world study of DLL3 expression in patients with small cell lung cancer [J ] . Lung Cancer ， 2020 ， 147 ： 237 - 243 .

Shen XB ， Wang Y ， Shan BJ ， et al . Prognostic significance of platelet-to-lymphocyte ratio（PLR） and mean platelet volume（MPV） during etoposide-based first-line treatment in small cell lung cancer patients [J ] . Cancer Management and Research ， 2019 ， 11 ： 8965 - 8975 .

Kadono Y ， Kawaguchi S ， Nohara T ， et al . Blood cell count biomarkers predicting efficacy of pembrolizumab as second-line therapy for advanced urothelial carcinoma [J ] . Anticancer Research ， 2021 ， 41 （ 3 ）： 1599 - 1606 .

Uchimoto T ， Nakamura K ， Komura K ， et al . Prognostic value of the fluctuation in the neutrophil-lymphocyte ratio at 6 weeks of pembrolizumab treatment is specific to the clinical response in metastatic urothelial carcinoma [J ] . Urology Oncology ， 2022 ， 40 （ 7 ）： 344.e11 - 344.e17 .

Kobayashi T ， Ito K ， Kojima T ， et al . Pre-pembrolizumab neutrophil-to-lymphocyte ratio（NLR） predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR [J ] . Cancer Immunology Immunotherapy ， 2022 ， 71 （ 2 ）： 461 - 471 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Pathogen distribution and predictive value of serum sTREM-1 and HBD-2 levels in patients with bronchial asthma complicated with pulmonary infection

Alterations of adenosine in tumor microenvironment and its impact on tumor treatment

An analysis of hot issues in immunotherapy for non-small cell lung cancer

Research advances in the interaction between tumor-associated macrophages and T cell subsets

Risk factors and prognosis of checkpoint inhibitor pneumonitis

Related Author

Cui Yunxiang

Hua Mao

Zhang Qingqing

Han Leng

Bai Dingyuan

Zhou Yuxuan

Zhu Xinting

Zhang Jiayu

Related Institution

Department of Respiratory and Critical Care Medicine，Qinghai University Affiliated Hospital

Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Cancer Center，Renmin Hospital of Wuhan University

Department of Oncology， The First Affiliated Hospital of Shandong First Medical University

School of Clinical Medicine，Shandong Second Medical University

⁰